Tech Center 1600 • Art Units: 1627
This examiner grants 50% of resolved cases
| App # | Title | Status | Assignee |
|---|---|---|---|
| 18043357 | PLASMA KALLIKREIN INHIBITORS | Final Rejection | Merck Sharp & Dohme LLC |
| 18015364 | ADENOSINE A2A AND A2B RECEPTOR DUAL ANTAGONISTS FOR IMMUNO-ONCOLOGY | Non-Final OA | Merck Sharp & Dohme LLC |
| 18015387 | ADENOSINE A2A AND A2B RECEPTOR DUAL ANTAGONISTS FOR IMMUNO-ONCOLOGY | Non-Final OA | Merck Sharp & Dohme LLC |
| 18007776 | RIPK1 INHIBITORS AND METHODS OF USE | Final Rejection | Merck Sharp & Dohme LLC |
| 18022296 | NANOPARTICLES CONTAINING MULTIPLE CLEAVABLE PRODUGS FOR CANCER THERAPY | Final Rejection | The University of Chicago |
| 18022017 | BIOINSPIRED LIPID DERIVATIVES AND USES THEREOF | Final Rejection | Ohio State Innovation Foundation |
| 18558766 | IPTACOPAN FOR THE TREATMENT OF ATYPICAL HEMOLYTIC UREMIC SYNDROME | Non-Final OA | Novartis AG |
| 18557241 | RING CLOSURE OF BENZOQUINONES CONTAINING AN UNSATURATED SIDE CHAIN USING A BASIC CATALYST | Non-Final OA | DSM IP Assets B.V. |
| 17917538 | COMPOSITIONS AND METHODS TO INHIBIT FOULING OF AMMONIUM SALTS | Non-Final OA | ECOLAB USA INC. |
| 18032724 | THIOBENZIMIDAZOLE DERIVATIVE OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF AND USE THEREOF | Non-Final OA | KOREA UNIVERSITY RESEARCH AND BUSINESS FOUNDATION |
| 18285650 | METHODS FOR OPTIMIZING THE TREATMENT OF COLORECTAL CANCER | Non-Final OA | Brown University |
| 18035478 | RAF INHIBITOR FOR TREATING LOW GRADE GLIOMA | Final Rejection | Dana-Farber Cancer Institute Inc. |
| 18285915 | METHOD FOR PREPARING DEUTERATED CHEMICAL BY MEANS OF DEUTERATION REACTION OF CARBON-HYDROGEN BOND WITH DEUTERIUM GAS UNDER CATALYSIS OF ALKALI | Non-Final OA | FUDAN UNIVERSITY |
| 18557236 | PROPHYLACTIC AND/OR THERAPEUTIC AGENT FOR AMYOTROPHIC LATERAL SCLEROSIS | Non-Final OA | NATIONAL UNIVERSITY CORPORATION TOKAI NATIONAL HIGHER EDUCATION AND RESEARCH SYSTEM |
| 18001074 | SMALL-MOLECULE INHIBITORS OF THE FRS2-FGFR INTERACTION AND THEIR USE IN MEDICINE, IN THE PREVENTION AND TREATMENT OF CANCER | Final Rejection | ETH ZÜRICH |
| 18084092 | BI-Heteroaryl Substitute 1,4-Benzodiazepines And Uses Thereof For The Treatment Of Cancer | Final Rejection | Janssen Pharmaceutica NV |
| 18020025 | THERAPEUTICALLY USEFUL CURE-PRO MOLECULES FOR E3 LIGASE MEDIATED DEGRADATION OF PROTEINS, AND METHODS OF MAKING AND USING THEM | Non-Final OA | CORNELL UNIVERSITY |
| 18020019 | THERAPEUTIC COMPOSITION OF CURE-PRO COMPOUNDS FOR TARGETED DEGRADATION OF BET DOMAIN PROTEINS, AND METHODS OF MAKING AND USAGE | Non-Final OA | CORNELL UNIVERSITY |
| 17769307 | METHODS OF INHIBITING LIVER-TYPE GLUTAMINASE, GLS2 | Non-Final OA | CORNELL UNIVERSITY |
| 18265740 | SMALL MOLECULES AS LARP1 LIGANDS | Final Rejection | UNIVERSITY OF PITTSBURGH-OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION |
| 18437733 | METHODS AND COMPOSITIONS FOR TREATING PULMONARY HYPERTENSION | Non-Final OA | MannKind Corporation |
| 18015657 | SUBSTITUTED 4-(3-AMINOPROP-1-YL)AMINOQUINOLINE ANALOGS AS MODULATORS OF MELANOMA-ASSOCIATED ANTIGEN 11 UBIQUITIN LIGASE | Non-Final OA | ST. JUDE CHILDREN'S RESEARCH HOSPITAL, INC. |
| 18019067 | MODIFIED EZETIMIBE DRUG FOR CANCER TREATMENT | Non-Final OA | University of South Africa |
| 17872533 | SEPARATION OF RARE EARTH METALS | Final Rejection | The Queen's University of Belfast |
| 18099113 | COMBINATION THERAPIES USING CASPASE-1 DEPENDENT ANTICANCER AGENTS AND PGE2 ANTAGONISTS | Final Rejection | Trustees of Tufts College |
| 17921369 | Nutritional Composition Comprising Carnitine and Method for Treating or Preventing an Infection in a Mammal | Non-Final OA | Lonza Greenwood LLC |
| 18033931 | PYRIMIDINE COMPOUNDS, COMPOSITIONS, AND MEDICINAL APPLICATIONS THEREOF | Final Rejection | Blueprint Medicines Corporation |
| 18005165 | ROCK INHIBITOR, AND PREPARATION METHOD THEREFOR AND USE THEREOF | Non-Final OA | WUHAN LL SCIENCE AND TECHNOLOGY DEVELOPMENT CO., LTD. |
| 18558806 | POLO LIKE KINASE 4 INHIBITORS | Non-Final OA | ORIC Pharmaceuticals, Inc. |
| 18558810 | NLRP3 INFLAMMASOME-INHIBITING COMPOUNDS AND THE USE THEREOF | Non-Final OA | UNIVERSITA' DI PISA (40%) |
IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.
Build Your Strategy